MA37994A2 - Compositions pharmaceutiques contenant un transporteur d'oxygène à base d'hémoglobine pour traitement ciblant un cancer et prévention de récidive de cancer - Google Patents
Compositions pharmaceutiques contenant un transporteur d'oxygène à base d'hémoglobine pour traitement ciblant un cancer et prévention de récidive de cancerInfo
- Publication number
- MA37994A2 MA37994A2 MA37994A MA37994A MA37994A2 MA 37994 A2 MA37994 A2 MA 37994A2 MA 37994 A MA37994 A MA 37994A MA 37994 A MA37994 A MA 37994A MA 37994 A2 MA37994 A2 MA 37994A2
- Authority
- MA
- Morocco
- Prior art keywords
- hemoglobin
- based oxygen
- cancer
- oxygen carrier
- cells
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 8
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 title abstract 6
- 201000011510 cancer Diseases 0.000 title abstract 6
- 229910052760 oxygen Inorganic materials 0.000 title abstract 6
- 239000001301 oxygen Substances 0.000 title abstract 6
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- 230000008685 targeting Effects 0.000 title abstract 2
- 230000002265 prevention Effects 0.000 title 1
- 102000001554 Hemoglobins Human genes 0.000 abstract 5
- 108010054147 Hemoglobins Proteins 0.000 abstract 5
- 210000004027 cell Anatomy 0.000 abstract 3
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 abstract 2
- 206010021143 Hypoxia Diseases 0.000 abstract 2
- 239000002246 antineoplastic agent Substances 0.000 abstract 2
- 229940127089 cytotoxic agent Drugs 0.000 abstract 2
- 230000001146 hypoxic effect Effects 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 102000005962 receptors Human genes 0.000 abstract 2
- 108020003175 receptors Proteins 0.000 abstract 2
- 101100372758 Danio rerio vegfaa gene Proteins 0.000 abstract 1
- 101150064607 HIF1A gene Proteins 0.000 abstract 1
- 206010027476 Metastases Diseases 0.000 abstract 1
- 108091027981 Response element Proteins 0.000 abstract 1
- 101150030763 Vegfa gene Proteins 0.000 abstract 1
- 101710097421 WD repeat and HMG-box DNA-binding protein 1 Proteins 0.000 abstract 1
- 102100029469 WD repeat and HMG-box DNA-binding protein 1 Human genes 0.000 abstract 1
- 230000006907 apoptotic process Effects 0.000 abstract 1
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 abstract 1
- 229960001467 bortezomib Drugs 0.000 abstract 1
- 230000030833 cell death Effects 0.000 abstract 1
- 229960004316 cisplatin Drugs 0.000 abstract 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 abstract 1
- 229960004679 doxorubicin Drugs 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 230000009401 metastasis Effects 0.000 abstract 1
- 210000000130 stem cell Anatomy 0.000 abstract 1
- 210000005102 tumor initiating cell Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/41—Porphyrin- or corrin-ring-containing peptides
- A61K38/42—Haemoglobins; Myoglobins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/38—Silver; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Inorganic Chemistry (AREA)
- Oncology (AREA)
- Pathology (AREA)
- Radiology & Medical Imaging (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261712853P | 2012-10-12 | 2012-10-12 | |
| US13/713,031 US20140106004A1 (en) | 2012-10-12 | 2012-12-13 | Hemoglobin-based oxygen carrier-containing pharmaceutical composition for cancer targeting treatment and prevention of cancer recurrence |
| PCT/US2013/064418 WO2014059199A1 (en) | 2012-10-12 | 2013-10-11 | Hemoglobin-based oxygen carrier-containing pharmaceutical composition for cancer targeting treatment and prevention of cancer recurrence |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA37994A2 true MA37994A2 (fr) | 2016-06-30 |
Family
ID=50475529
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA37994A MA37994A2 (fr) | 2012-10-12 | 2013-10-11 | Compositions pharmaceutiques contenant un transporteur d'oxygène à base d'hémoglobine pour traitement ciblant un cancer et prévention de récidive de cancer |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US20140106004A1 (enExample) |
| EP (1) | EP2906222A4 (enExample) |
| JP (1) | JP6113850B2 (enExample) |
| KR (1) | KR20150065881A (enExample) |
| CN (1) | CN104717966B (enExample) |
| AP (1) | AP2015008315A0 (enExample) |
| AR (1) | AR093023A1 (enExample) |
| AU (1) | AU2013329121B2 (enExample) |
| BR (1) | BR112015007475A2 (enExample) |
| CA (1) | CA2884521C (enExample) |
| CL (1) | CL2015000897A1 (enExample) |
| EA (1) | EA201500301A1 (enExample) |
| IL (1) | IL237763A (enExample) |
| MA (1) | MA37994A2 (enExample) |
| MX (1) | MX367562B (enExample) |
| PH (1) | PH12015500562B1 (enExample) |
| SG (3) | SG10201608747RA (enExample) |
| TW (1) | TW201414489A (enExample) |
| UY (1) | UY35082A (enExample) |
| WO (1) | WO2014059199A1 (enExample) |
| ZA (1) | ZA201501949B (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY176175A (en) * | 2013-05-13 | 2020-07-24 | Vision Global Holdings Ltd | Pharmaceutical composition comprising modified hemoglobin-based therapeutic agent for cancer targeting treatment and diagnostic imaging |
| CN106536056B (zh) | 2014-06-13 | 2021-07-16 | 儿童医学中心公司 | 分离线粒体的产品和方法 |
| US9814759B2 (en) * | 2014-07-02 | 2017-11-14 | Cheer Global Ltd. | Pharmaceutical composition comprising recombinant hemoglobin protein or subunit-based therapeutic agent for cancer targeting treatment |
| EP4620519A3 (en) | 2015-11-30 | 2025-10-22 | Sana Biotechnology, Inc. | Methods and compositions relating to chondrisomes from blood products |
| EP3402490B1 (en) | 2016-01-15 | 2022-06-01 | The Children's Medical Center Corporation | Therapeutic use of mitochondria and combined mitochondrial agents |
| US20230190947A1 (en) * | 2016-06-21 | 2023-06-22 | Therapure Biopharma Inc. | Hemoglobin-Targeted Drug Delivery For The Treatment of Cancer |
| WO2018195434A1 (en) | 2017-04-21 | 2018-10-25 | Lisanti Michael P | Vitamin c and doxycycline: a synthetic lethal combination therapy for eradicating cancer stem cells (cscs) |
| EP3612177A4 (en) * | 2017-04-21 | 2021-01-13 | Lunella Biotech, Inc. | TARGETING HYPOXIC CARCINOUS STEM CELLS (SCC) USING DOXYCYCLINE: IMPLICATIONS FOR IMPROVING ANTI-ANGIOGENIC THERAPY |
| CA3063717C (en) | 2017-05-19 | 2021-08-24 | Lunella Biotech, Inc. | Antimitoscins: targeted inhibitors of mitochondrial biogenesis for eradicating cancer stem cells |
| WO2018213764A1 (en) | 2017-05-19 | 2018-11-22 | Lunella Biotech, Inc. | Companion diagnostics for mitochondrial inhibitors |
| BR112019026097A2 (pt) | 2017-06-26 | 2020-07-07 | Lunella Biotech, Inc. | mitoketoscins: terapêuticos à base de mitocôndrias com direcionamento no metabolismo da cetona em células cancerígenas |
| JPWO2019124423A1 (ja) * | 2017-12-19 | 2020-10-22 | 国立大学法人 岡山大学 | がんの進行抑制、治療、予防及び／又は再発予防剤 |
| CN111558032B (zh) * | 2020-05-19 | 2023-08-22 | 中国科学院宁波材料技术与工程研究所 | 一种蛋白纳米药物及其制备方法与应用 |
| CN114344263B (zh) * | 2022-02-21 | 2023-08-01 | 杭州普略生物科技有限公司 | 一种用于靶向巨噬细胞增强肿瘤治疗效果的纳米蛋白胶束及其制备方法和应用 |
| KR102793996B1 (ko) | 2022-03-31 | 2025-04-09 | 충남대학교산학협력단 | 저산소증 완화능을 갖는 페길화 헤모글로빈 나노클러스터를 포함하는 항암 화학-광역학 치료용 조성물 |
| WO2025222059A1 (en) * | 2024-04-17 | 2025-10-23 | Prolong Pharmaceuticals Llc | Method of treating cancer using pegylated bovine hemoglobin |
| CN119746044A (zh) * | 2025-03-06 | 2025-04-04 | 润方（北京）生物医药研究院有限公司 | 血红蛋白氧载体在制备抗病毒药物中的应用 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5478806A (en) * | 1989-11-22 | 1995-12-26 | Enzon, Inc. | Enhancement of antitumor therapy with hemoglobin-based conjugates |
| CA2236344A1 (en) * | 1998-04-30 | 1999-10-30 | Hemosol Inc. | Hemoglobin-haptoglobin complexes |
| US20050164915A1 (en) * | 2002-04-01 | 2005-07-28 | Sangart, Inc. | Compositions for oxygen transport comprising a high oxygen affinity modified hemoglobin |
| US20050202559A1 (en) * | 2002-10-29 | 2005-09-15 | Scott Pownall | Cancer treatment by metabolic modulations |
| JP2012515792A (ja) * | 2009-01-23 | 2012-07-12 | キャンサー・リサーチ・テクノロジー・リミテッド | ヘッジホッグ経路阻害剤 |
| SI2440239T1 (en) * | 2009-06-09 | 2018-01-31 | Prolong Pharmaceuticals, LLC | Hemoglobin compositions |
| CN102573853A (zh) * | 2009-07-07 | 2012-07-11 | 诺尔姆奥克西斯公司 | 使用肌醇三焦磷酸减少多药抗性的方法 |
| US8808748B2 (en) * | 2010-04-20 | 2014-08-19 | Vindico NanoBio Technology Inc. | Biodegradable nanoparticles as novel hemoglobin-based oxygen carriers and methods of using the same |
| US7989593B1 (en) * | 2010-05-27 | 2011-08-02 | Bing Lou Wong | Method for the preparation of a high-temperature stable oxygen-carrier-containing pharmaceutical composition and the use thereof |
| US7932356B1 (en) * | 2010-06-23 | 2011-04-26 | Bing Lou Wong | Method for the preparation of a heat stable oxygen carrier-containing pharmaceutical composition |
| US20110319332A1 (en) * | 2010-06-23 | 2011-12-29 | Bing Lou Wong | Treatment methods using a heat stable oxygen carrier-containing pharmaceutical composition |
| US8048856B1 (en) * | 2010-06-23 | 2011-11-01 | Billion King, Ltd. | Treatment methods using a heat stable oxygen carrier-containing pharmaceutical composition |
-
2012
- 2012-12-13 US US13/713,031 patent/US20140106004A1/en not_active Abandoned
-
2013
- 2013-10-11 MA MA37994A patent/MA37994A2/fr unknown
- 2013-10-11 BR BR112015007475A patent/BR112015007475A2/pt not_active IP Right Cessation
- 2013-10-11 WO PCT/US2013/064418 patent/WO2014059199A1/en not_active Ceased
- 2013-10-11 EP EP13844670.3A patent/EP2906222A4/en not_active Ceased
- 2013-10-11 AU AU2013329121A patent/AU2013329121B2/en not_active Ceased
- 2013-10-11 KR KR1020157012185A patent/KR20150065881A/ko not_active Ceased
- 2013-10-11 CN CN201380053346.1A patent/CN104717966B/zh not_active Expired - Fee Related
- 2013-10-11 JP JP2015536905A patent/JP6113850B2/ja not_active Expired - Fee Related
- 2013-10-11 CA CA2884521A patent/CA2884521C/en active Active
- 2013-10-11 SG SG10201608747RA patent/SG10201608747RA/en unknown
- 2013-10-11 SG SG11201502133SA patent/SG11201502133SA/en unknown
- 2013-10-11 AP AP2015008315A patent/AP2015008315A0/xx unknown
- 2013-10-11 EA EA201500301A patent/EA201500301A1/ru unknown
- 2013-10-11 SG SG10201607846PA patent/SG10201607846PA/en unknown
- 2013-10-11 MX MX2015004512A patent/MX367562B/es active IP Right Grant
- 2013-10-14 UY UY35082A patent/UY35082A/es not_active Application Discontinuation
- 2013-10-14 TW TW102136951A patent/TW201414489A/zh unknown
- 2013-10-15 AR ARP130103741A patent/AR093023A1/es unknown
-
2014
- 2014-06-19 US US14/308,725 patent/US9056098B2/en active Active
-
2015
- 2015-03-16 IL IL237763A patent/IL237763A/en active IP Right Grant
- 2015-03-16 PH PH12015500562A patent/PH12015500562B1/en unknown
- 2015-03-20 ZA ZA2015/01949A patent/ZA201501949B/en unknown
- 2015-04-09 CL CL2015000897A patent/CL2015000897A1/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA37994A2 (fr) | Compositions pharmaceutiques contenant un transporteur d'oxygène à base d'hémoglobine pour traitement ciblant un cancer et prévention de récidive de cancer | |
| Tian et al. | Targeting the integrated stress response in cancer therapy | |
| Heffeter et al. | The ruthenium compound KP1339 potentiates the anticancer activity of sorafenib in vitro and in vivo | |
| Petruzzella et al. | Triple action Pt (iv) derivatives of cisplatin: A new class of potent anticancer agents that overcome resistance | |
| Murta-Nascimento et al. | Epidemiology of urinary bladder cancer: from tumor development to patient’s death | |
| Kalal et al. | Chemotherapy resistance mechanisms in advanced skin cancer | |
| Weisberg et al. | FLT3 inhibition and mechanisms of drug resistance in mutant FLT3-positive AML | |
| Tiacci et al. | Targeting mutant BRAF in relapsed or refractory hairy-cell leukemia | |
| Lam et al. | Bacillus Calmete-Guérin plus interferon-α2B intravesical therapy maintains an extended treatment plan for superficial bladder cancer with minimal toxicity | |
| Mahgoub et al. | The role of autophagy in colorectal cancer: Impact on pathogenesis and implications in therapy | |
| Margue et al. | Kinase inhibitor library screening identifies synergistic drug combinations effective in sensitive and resistant melanoma cells | |
| MA38571B1 (fr) | Composition pharmaceutique comprenant un agent thérapeutique à base d'hémoglobine modifiée pour un traitement de ciblage du cancer et imagerie diagnostique | |
| Tomao et al. | Overcoming platinum resistance in ovarian cancer treatment: from clinical practice to emerging chemical therapies | |
| Mert et al. | Synergistic effect of MEK inhibitor and metformin combination in low grade serous ovarian cancer | |
| Al-Hussaini et al. | Small molecule inhibitors in acute myeloid leukemia: from the bench to the clinic | |
| Kanjanapan et al. | Niraparib for the treatment of ovarian cancer | |
| Deng et al. | Mitochondrial dynamin-related protein Drp1: a new player in cardio-oncology | |
| Wolf | Inhibitor of apoptosis proteins as therapeutic targets in bladder cancer | |
| MA34952B1 (fr) | Combinaisons comprenant du macitentan pour le traitement d'un glioblastome multiforme | |
| Lee et al. | Avelumab first-line maintenance plus best supportive care (BSC) vs. BSC alone for advanced urothelial carcinoma: JAVELIN Bladder 100 Asian subgroup analysis | |
| Consoli et al. | Navigating heme pathways: the breach of heme oxygenase and hemin in breast cancer | |
| Ghisoni et al. | Veliparib: a new therapeutic option in ovarian cancer? | |
| Nemati et al. | Clinical relevance of human cancer xenografts as a tool for preclinical assessment: example of in-vivo evaluation of topotecan-based chemotherapy in a panel of human small-cell lung cancer xenografts | |
| Schrauwen et al. | The antitumor effect of metformin with and without carboplatin on primary endometrioid endometrial carcinoma in vivo | |
| RU2009134479A (ru) | Противоопухолевая активность ссi-779 при папиллярном раке клеток почечного эпителия |